MarketCap
Facebook
X
TelegramQuartalsbericht 2022-Q3
hinzugefügt 08.11.2022
Albireo Pharma ROA 2011-2026 | ALBO
ROA Jährlich Albireo Pharma
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -11.27 | -37.69 | -37.99 | -24.86 | -33.34 | -47.65 | -45.23 | -55.58 | -46.99 | -50.44 | -25.52 |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| -11.27 | -55.58 | -37.87 |
ROA Vierteljährlich Albireo Pharma
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -45.45 | -26.2 | 4.83 | 5.68 | -14.84 | -25.61 | -55.63 | -46.25 | -29.0 | -42.28 | -44.79 | -47.64 | -33.44 | -41.0 | -35.29 | -33.09 | -16.31 | -25.2 | -26.53 | -27.09 | -26.44 | -34.55 | -33.78 | -21.03 | -10.33 | -56.43 | -85.74 | -105.65 | -110.62 | -86.8 | -95.95 | -92.96 | -99.9 | -84.23 | -39.62 | -74.0 | -61.51 | -64.74 | -77.05 | -80.51 | -83.49 | -85.47 | -61.22 | -431.9 | -433.83 | 9.96 | -421.12 | -10.84 |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 9.96 | -433.83 | -72.19 |
ROA anderer Aktien in der Pharmaeinzelhändler
| Name | ROA | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-20.13 | - | 2.43 % | $ 254 M |  Germany |
 |
Heron Therapeutics
HRTX
|
-7.89 | $ 0.79 | 1.9 % | $ 132 M |  USA |
 |
Altimmune
ALT
|
-31.47 | $ 3.44 | 2.99 % | $ 303 M | USA |
 |
I-Mab
IMAB
|
7.43 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.33 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
23.87 | - | 2.54 % | $ 160 B |  France |
 |
Ascendis Pharma A/S
ASND
|
-35.36 | $ 218.03 | -1.74 % | $ 5 B |  Danmark |
 |
Biophytis SA
BPTS
|
-89.6 | - | -13.47 % | $ 169 M | France |
 |
Midatech Pharma plc
MTP
|
-42.28 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-53.39 | - | -1.52 % | $ 24.7 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-27.57 | - | - | $ 26.5 M | USA |
 |
ARCA biopharma
ABIO
|
-21.14 | - | 1052.0 % | $ 415 M | USA |
 |
Aeterna Zentaris
AEZS
|
-10.45 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-123.72 | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
-232.99 | - | -24.86 % | $ 820 K | USA |
 |
Aileron Therapeutics
ALRN
|
-101.11 | - | 10.36 % | $ 9.8 M | USA |
 |
Acasti Pharma
ACST
|
-13.29 | - | 4.01 % | $ 150 M | Canada |
 |
Incyte Corporation
INCY
|
18.49 | $ 90.43 | -0.21 % | $ 17.7 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
4.82 | - | - | - |  Russia |
 |
Inovio Pharmaceuticals
INO
|
-79.04 | $ 1.54 | -2.41 % | $ 34.1 M | USA |
 |
Avenue Therapeutics
ATXI
|
-437.72 | - | -52.27 % | $ 4.45 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-72.8 | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
-225.71 | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
-289.96 | - | -9.65 % | $ 45.9 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-489.29 | - | - | $ 7.46 M |  Israel |
 |
Cullinan Management
CGEM
|
-49.04 | $ 13.57 | 7.1 % | $ 818 M | USA |
 |
Atreca
BCEL
|
-62.67 | - | -11.76 % | $ 5.79 M | USA |
 |
BioDelivery Sciences International
BDSI
|
26.14 | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
3.5 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Inventiva S.A.
IVA
|
-40.69 | $ 6.07 | 4.97 % | $ 138 M | France |
 |
Calithera Biosciences
CALA
|
-177.73 | - | -10.95 % | $ 876 K | USA |
 |
Cara Therapeutics
CARA
|
-94.17 | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
-30.95 | - | - | $ 3.74 B | USA |
 |
Bellerophon Therapeutics
BLPH
|
-249.92 | - | -74.18 % | $ 955 K | USA |
 |
KalVista Pharmaceuticals
KALV
|
-73.15 | $ 16.82 | -1.06 % | $ 835 M | Britain |
 |
Checkpoint Therapeutics
CKPT
|
-752.78 | - | - | $ 169 M | USA |
 |
Clovis Oncology
CLVS
|
-55.94 | - | -7.23 % | $ 13 M | USA |
 |
Kamada Ltd.
KMDA
|
-0.7 | $ 8.27 | 0.24 % | $ 260 M | Israel |
 |
Aeglea BioTherapeutics
AGLE
|
-19.95 | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-35.55 | - | - | $ 867 M | Germany |
 |
Compugen Ltd.
CGEN
|
22.57 | $ 2.13 | 1.67 % | $ 199 M | Israel |
 |
Karyopharm Therapeutics
KPTI
|
-46.48 | $ 7.11 | -6.82 % | $ 866 K | USA |
 |
Denali Therapeutics
DNLI
|
-30.77 | $ 20.99 | 4.07 % | $ 3.45 B | USA |
 |
Keros Therapeutics
KROS
|
25.74 | $ 11.16 | 1.82 % | $ 415 M | USA |
 |
Akero Therapeutics
AKRO
|
-30.52 | - | - | $ 3.67 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
-50.45 | $ 4.35 | 2.48 % | $ 722 M | Canada |
 |
Akouos
AKUS
|
-31.09 | - | 0.23 % | $ 488 M | USA |
 |
AIkido Pharma
AIKI
|
-31.2 | - | 1.93 % | $ 17.4 M | USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
-273.86 | - | -5.98 % | $ 34.1 M | USA |